A Look At MBX Biosciences (MBX) Valuation After Recent Share Price Pullback

Why MBX Biosciences is on investors’ radar today

MBX Biosciences (MBX) has attracted attention after a recent move in its share price, with the stock now around $28 following mixed short term returns, including a decline over the past month and a modest gain over the past 3 months.

See our latest analysis for MBX Biosciences.

That recent pullback, with a 30 day share price return of around 26% decline and year to date share price return of around 8% decline, contrasts sharply with a very large 1 year total shareholder return of about 216%. This still reflects strong past interest in MBX Biosciences’ story.

If you are looking beyond MBX Biosciences for other potential ideas in related areas, this could be a useful moment to scan 34 healthcare AI stocks.

So with MBX Biosciences sitting around $28, a value score of 1 and analysts’ average price target near $61, should you see the recent pullback as a potential entry point, or assume the market is already pricing in future growth?

Preferred multiple of Price to Book: Is it justified?

Analysts looking at MBX Biosciences often turn to the P/B ratio, which currently sits around 3.6x, to frame the $28 share price.

P/B compares the company’s market value to its net assets, so it can be a useful reference for a clinical stage business with no meaningful revenue and ongoing losses.

Relative to a peer average P/B of 8.4x, MBX Biosciences is described as good value on this measure, which implies the market is assigning a lower premium to its asset base than many similar companies.

However, compared with the broader US pharmaceuticals group, where the average P/B is 2.1x, MBX Biosciences trades at a higher multiple, so investors are still paying more than the sector average for each dollar of book value.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price to Book of 3.6x (ABOUT RIGHT)

However, you also need to weigh clinical and regulatory setbacks for its pipeline, as well as the ongoing net loss of about US$87 million, as potential pressure points.

Find out about the key risks to this MBX Biosciences narrative.

Next Steps

If the mix of strong past returns and current risks leaves you undecided, it could be worth moving quickly and checking the detail for yourself so you can weigh the trade off using 5 important warning signs.

Looking for more investment ideas?

If MBX Biosciences has caught your attention, do not stop there. Widening your watchlist with other focused ideas could help you spot opportunities earlier than the crowd.

• Spot potential value opportunities before others by running through the 49 high quality undervalued stocks that filters for quality businesses trading below their assessed worth.
• Prioritise resilience and capital protection by screening companies using the 74 resilient stocks with low risk scores that focuses on businesses with lower risk profiles.
• Seek out future leaders hiding in plain sight by checking the screener containing 26 high quality undiscovered gems that highlights underfollowed companies with solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com